Development of Specific "Drug-Like Property" Rules for Carboxylate-Containing Oral Drug Candidates

The carboxylate moiety is an important pharmacophore in the medicinal chemist's arsenal and is sometimes an irreplaceable functionality in drug–target interactions. Thus, practical guidance on its use in the most optimized manner would be a welcome addition to rational drug design. Key physicochemical and ADMET‐PK properties from a dataset of drugs containing a carboxylate (COOH) moiety were assembled and compared with those of a broader, general drug dataset. Our main objective was to identify features specific to COOH‐containing oral drugs that could be converted into simple rules delineating the boundaries within which prospective COOH‐containing chemical series and COOH‐containing drug candidates would be reasonably expected to possess properties suitable for oral administration. These specific “drug‐like” property rules include molecular weight, the number of rotatable bonds, the number of hydrogen bond donors and acceptors, predictions of lipophilic character (calculated log P and log D values), topological polar surface area (TPSA), and the pKa value of the carboxylate moiety. Similar to the various sets of criteria that have emerged over the past decade and which have significantly reshaped the way medicinal chemists think about preferred drug chemical space, we propose these specific COOH “drug‐like” property rules as a guide for the design of superior COOH‐containing drug candidates and as a tool to better manage the liabilities generally associated with the presence of a COOH moiety. Acid rules! The carboxylate moiety is an important pharmacophore in medicinal chemistry and is often irreplaceable in drug–target interactions. Based on an analysis of key physicochemical and ADMET‐PK properties of oral drugs, we propose “drug‐like” property rules for carboxylic acids that can help in the design of better drug candidates and decrease liabilities generally associated with acids.